Successfully managing a chronic disease like cystic fibrosis means more than just taking medications. It requires trusting partnerships between people with CF and their families with their CF care teams to develop treatment plans that line up personal life goals with health goals.
Site Search
HM Insurance Group (HM) raises nearly $40,000 through sharing the emotional 65 Roses® story and selling roses at their national sales conference.
CARSTAR was recognized as a National Corporate Champion and was presented the Rising Star Award at the 16th annual Volunteer Leadership Conference in San Diego.
For the second year, Mastercard® becomes the Greater New York Chapter's top corporate sponsor thanks to two senior-level executives personally affected by cystic fibrosis who initially connected employees to the mission of the Cystic Fibrosis Foundation.
Choate Construction's 9th annual Cars & 'Q for the Cause raised over $435,400 for the Cystic Fibrosis Foundation, serving as a role model for corporations looking to integrate philanthropy into their business model.
Nutritional support is a vital component of care for patients with cystic fibrosis. These recommendations cover caloric intake, dosing for pancreatic enzyme replacement therapy, and monitoring growth in childhood and weight status in patients of all ages.
To help standardize the diagnosis of both infants with positive newborn screening results and older patients with what may be cystic fibrosis symptoms, the Cystic Fibrosis Foundation worked with CF medical experts to develop guidelines on the steps leading to a confirmed diagnosis.
Most newborns in the United States are screened for CF at birth through newborn
Updated from 2003, these guidelines on infection prevention and control for cystic fibrosis provide recommendations for people with CF, their families, and health care providers to help reduce the spread of germs in the clinic and hospital setting, as well as in everyday life.
Nontuberculous mycobacteria can cause chronic pulmonary infection or can reside in the lungs without causing progressive disease. Challenges include making decisions on when and how to initiate treatment.